Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials

BACKGROUND: Manifold data have demonstrated that the addition of bevacizumab to chemotherapy improved progression-free survival (PFS), while few trials have revealed its significant overall survival (OS) benefit. Furthermore, it still remains suspended how to maximize the benefits of bevacizumab as...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Cunfu, Xiang, Aizhai, Chen, Xianzhi, Yin, Kai, Lu, Jinsong, Yin, Wenjin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499926/
https://www.ncbi.nlm.nih.gov/pubmed/28721065
http://dx.doi.org/10.2147/OTT.S138600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499926/
https://www.ncbi.nlm.nih.gov/pubmed/28721065
http://dx.doi.org/10.2147/OTT.S138600

Ejemplares similares